• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Acta ophthalmologica >Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
【24h】

Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.

机译：连续三个月注射一次后，根据个别确定的注射策略，使用玻璃体内贝伐单抗治疗新血管性年龄相关性黄斑变性12个月的疗效。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: To report the results of intravitreal treatment with bevacizumab in neovascular age-related macular degeneration (AMD) after a loading dose (LD) of three monthly injections followed by an optical coherence tomography (OCT)-guided strategy, based on best-corrected visual acuity (VA) and number of injections required over 1 year. METHODS: A series of consecutive cases of 149 eyes of 147 patients received three or more intravitreal injections of bevacizumab (1.25 mg) for neovascular AMD over a 1-year period. The patients underwent ophthalmological examinations: measurement of the VA, fluorescein angiography, dilated fundus examination at baseline; VA, OCT and dilated fundus examination at monthly follow-up visits. Repeated injections were given each month for the first 3 months (LD); thereafter, injections were only administered if leakage or macular oedema were present. RESULTS: Mean baseline VA was 51 +/- 14 letters, which improved to 58 +/- 15 letters (p < 0.0001; n = 149) at first evaluation (15 +/- 2 weeks), 59 +/- 15 letters (p < 0.0001; n = 143) at second evaluation (25 +/- 2 weeks) and 57 +/- 16 letters (p < 0.0001; n = 132) at third evaluation (51 +/- 3 weeks). The baseline mean central retinal thickness (344.6 mum) and total macular volume (8.6 mm(3) ) decreased at first evaluation, to 219.0 mum (p < 0.0001) and 7.2 mm(3) (p < 0.0001), respectively. The mean number of injections per patient treated for 1 year was 5.1 (range 3-9). No systemic side-effects were noted. CONCLUSION: Treatment of neovascular AMD with intravitreal bevacizumab administered in LD of three monthly injections and followed by an OCT-guided strategy provides functional and anatomical improvements for up to 1 year.
机译：目的：报告贝伐珠单抗玻璃体腔内治疗在三个月一次注射剂量（LD）后，基于最佳校正的光学相干断层扫描（OCT）指导策略，对新生血管性年龄相关性黄斑变性（AMD）进行玻璃体内治疗的结果视力（VA）和一年以上所需的注射次数。方法：在147例患者中，一系列149眼的连续病例在1年期间接受了3次或更多次玻璃体内注射贝伐单抗（1.25 mg）的新生血管AMD治疗。患者接受眼科检查：VA的测量，荧光素血管造影，基线时眼底膨胀检查;每月随访时进行VA，OCT和眼底扩大检查。在头3个月（LD）中，每月重复注射一次;此后，仅在出现渗漏或黄斑水肿时才进行注射。结果：平均基线VA为51 +/- 14个字母，在初次评估（15 +/- 2周）时提高到58 +/- 15个字母（p <0.0001; n = 149），59 +/- 15个字母（p在第二次评估（25 +/- 2周）时为p <0.0001; n = 143），在第三次评估（51 +/- 3周）时为57 +/- 16个字母（p <0.0001; n = 132）。在第一次评估时，基线平均视网膜中央平均厚度（344.6毫米）和总黄斑体积（8.6毫米（3））降低至219.0毫米（p <0.0001）和7.2毫米（3）（p <0.0001）。每位接受1年治疗的患者的平均注射次数为5.1（范围3-9）。没有发现全身性副作用。结论：玻璃体腔注射贝伐单抗在LD中每月3次注射，随后OCT指导策略治疗新血管性AMD，可提供长达一年的功能和解剖学改善。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号